Vertex Pharmaceuticals stock

VRTX · NASDAQ · USD

$538.60Change from previous close: −0.74%Absolute change: −$4.02

Close · November 13, 2026

Price history

+23.95% over the period

1 year: from $434.52 (November 13, 2025) to $538.60 (November 13, 2026), +23.95%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$538.60
October 30, 2026$558.88
September 30, 2026$522.81
August 31, 2026$544.52
July 31, 2026$477.10
June 30, 2026$496.73
May 29, 2026$447.54
April 30, 2026$427.38
March 31, 2026$446.54
February 27, 2026$496.83
January 30, 2026$469.90
December 31, 2025$453.36
November 28, 2025$433.61
November 13, 2025$434.52

At a glance

  • The company

    Biotechnology company developing transformative medicines for serious diseases including cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain

  • Latest results

    Quarter to September 30, 2026 · EPS $4.76 (estimate $4.76)

TickerLandia's take on Vertex Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$412.27
52-wk high$568.67

−5.29% from the 52-week high

Analysts · 32 analysts

Average target$595.36+10.54% vs. price

Buy 26 · Hold 5 · Sell 1 · Buy

TickerLandia Fingerprint: Vertex Pharmaceuticals

Compared with similar companies: low risk, strong momentum, and high profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Vertex Pharmaceuticals is pricier than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Vertex Pharmaceuticals's P/E today is 35.2, above the median of its last 8 fiscal years (26.8; between 20.5 and 144.1 from 2017 to 2025). Vertex Pharmaceuticals's P/E (trailing 12 months): 34.7, in line with the median of a group of 7 similar companies (34.7).

P/E compared with its history

Compared with 7 similar companies

Vertex Pharmaceuticals's metrics compared with similar companies
MetricVertex PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)34.7Middle
Forward P/E27.0Middle
Operating margin37.8%High
ROE20.8%High
Debt/equity0.31Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Vertex Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$3.44B

Latest quarter · Q3 2026

Net income

$653.6M

Latest quarter · Q3 2026

Quarterly net margin

19.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$136.56B
P/E
34.7
EPS
$15.54
Volume
750.53K
Daily trading
€754.15M
Dividend yield
0.00%

How Vertex Pharmaceuticals is changing

All results
  • Revenue grew 14.1% a year on average over the last 5 years

  • Operating margin fell from 48.2% to 34.8%

  • Free cash flow equal to 82% of net income

Returns

Vertex Pharmaceuticals returns

$1,000 invested in Vertex Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $2,882 today: +188.24% in total, +23.61% per year. This is the price return only: dividends are excluded.

PeriodVertex PharmaceuticalsS&P 500$1,000 becomes
1 month+11.00%−3.12%$1,110
6 months+18.88%+1.58%$1,189
Year to date+18.80%+10.46%$1,188
1 year+23.95%+12.23%$1,240
3 years+42.14%+71.41%$1,421
5 years+188.24%+61.48%$2,882
10 years+470.43%+249.40%$5,704

Over the last 6 months it has done better than 53% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Vertex Pharmaceuticals: technical analysis

Vertex Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.6% below its all-time closing high ($558.88, October 30, 2026).

Trend
Upward
RSI (14 sessions)
53
Between 30 and 70
vs 200-session average
+11.43%

Support and resistance

Price areas where Vertex Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$557.97+3.60%2 touches, last on September 3, 2026
  2. Last price$538.60
  3. Support$531.78−1.27%2 touches, last on September 28, 2026
  4. Support$498.54−7.44%5 touches, last on October 5, 2026
  5. Support$485.53−9.85%3 touches, last on October 13, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.44
Volatility (60 sessions, annualised)
25.7%
Largest fall in the last year
−15.21%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Vertex Pharmaceuticals: seasonality

Average monthly price change over 36 years

+3.4%Jan+0.2%Feb−2.2%Mar+1.6%Apr+7.7%May+3.2%Jun−0.7%Jul+4.9%Aug+2.8%Sep+0.3%Oct−2.0%Nov+7.2%Dec

Over the last 36 years, the strongest month for Vertex Pharmaceuticals has been May: +7.69% on average, positive in 20 years out of 35. The weakest has been March: −2.20% on average, positive in 15 years out of 35. November, the current month, has been positive in 17 years out of 35 (−2.03% on average).

Show chart data
MonthAverageMedianPositive years
January+3.44%+3.70%23 of 35
February+0.16%−1.13%16 of 35
March−2.20%−1.84%15 of 35
April+1.63%+3.13%21 of 35
May+7.69%+4.06%20 of 35
June+3.18%+0.90%20 of 35
July−0.65%−0.25%16 of 35
August+4.89%+2.70%23 of 36
September+2.83%−0.38%17 of 36
October+0.28%+1.87%20 of 36
November−2.03%−1.33%17 of 35
December+7.16%+5.73%23 of 35

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Vertex Pharmaceuticals and its competitors

Sales reach patients in the United States, Europe and other countries, with the United States accounting for 62.9% of revenue, Europe for 28.8% and the rest of the world for 8.3%. The biotechnology company offers cystic fibrosis medicines such as TRIKAFTA/KAFTRIO, ORKAMBI and KALYDECO, as well as CASGEVY for sickle cell disease and transfusion dependent beta thalassemia, and JOURNAVX for acute pain in adults. Its pipeline includes candidates for APOL1-mediated kidney disease, type 1 diabetes and myotonic dystrophy type 1. Customers include specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals and clinics.

Headquarters
Boston, United States
Employees
6,400
Founded
1989
Chief executive
Reshma Kewalramani
Vertex Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Vertex PharmaceuticalsVRTX$136.56B37.8%34.7+18.88%
Regeneron PharmaceuticalsREGN$98.84B30.4%21.1+32.73%
ModernaMRNA$90.38B-80.8%—+343.02%
argenxARGX$60.37B31.9%33.3+19.60%
BeOne MedicinesONC$47.58B17.8%53.4+31.59%
Royalty PharmaRPRX$39.85B64.4%45.3+30.16%

Same industry or related industries, similar size. Compare Vertex Pharmaceuticals with its competitors · Full profile